There was no significant change in body weight from baseline (before tolvaptan treatment) between patients with and without HCC (P = 0.2248), with albumin levels of < 2.5 g/dL and ≥ 2.5 g/dL (P = 0.3372), and serum sodium levels of < 125 mEq/L and ≥ 125 mEq/L (P = 0.2222). This evidence concerns the gene ALB and hepatocellular carcinoma.